Suppression of "rubral" tremor with levodopa

Lesions of the projection pathways from the dentate to the ventro-lateral thalamic nucleus in the environs of the red nucleus produce an intractable "rubral" tremor, which has a frequency of around 4 Hz and is present similarly at rest and through posture and action. Rubral tremor is thought to be related to the resting tremor of Parkinson's disease, for they are indistinguishable in frequency¹ and both entail synchronous rhythmical activity in VL thalamus neurones.² Levodopa has a variable suppressive effect on Parkinsonian resting tremor,³ and the rationale for its action is that it repletes diminished concentrations of dopamine in the striatum thereby restoring its inhibitory influence on the thalamus.⁴

Because of the similarities between rubral and Parkinsonian tremor we evaluated levodopa treatment in a patient with a mesencephalic angioma producing intractable tremor, the lesion being so circumscribed that it provided a paradigm of rubral tremor. Previously levodopa has been shown to suppress tremor arising from electrolytic lesions of the dentate and interpositus nuclei in monkeys (*Macaca mulatta*).⁵

Case report

The patient, a 51-year-old, right-handed man, was well until 1957 when he had sudden onset of severe headache followed by loss of consciousness. Subsequent investigations confirmed that he had had a subarachnoid haemorrhage. Angiography showed an arteriovenous malformation arising from near to the tip of the basilar artery in the interpeduncular fossa with a large anomalous draining vein passing through the mid brain to the right of the mid line. His permanent neurological deficits were a fixed, dilated right pupil with impaired ocular movement on the right in all directions save for abduction. He had a mild left-sided spastic hemiparesis. Six weeks after the acute episode he developed involuntary movements of the left hand which became more severe over the next six months and progressed to affect the whole arm and, to a lesser extent, the left leg. The tremor of the arm was a large amplitude, violent tremor at rest, more appreciable distally, which persisted and was exaggerated throughout voluntary movement and posture. Unrestrained the tremor could be self-injuring and necessitated wearing a large restraining harness. The tremor of the leg was intermittent and less severe and did not significantly impair gait. Because of the site of the lesion he was considered unsuitable for surgical treatment and during the years various drugs, including tetra benzine, diazepam, clonazepam, and orphenadrine, were tried without effect.

The patient was laid on a couch with his left arm outstretched, the fingers strapped down to prevent the arm from moving wildly. An accelerometer was mounted on the dorsum of his hand and the signals were fed to a digital computer which measured the frequency and amplitude of the tremor. During one hour of baseline recordings the tremor had a constant frequency of 3.8 Hz and an average peak acceleration of 1 g ($g = 981 \text{ cm/s}^2$). He was then given a single oral dose of levodopa (Sinemet 275) and observed for an hour. His vigilance was maintained with conversation and arithmetic. After five minutes his tremor began to decrease in amplitude until by the end of the hour the mean peak acceleration was one-eightieth of the initial value (figure), and remained so for five hours. In view of this response he was started on incremental doses of Sinemet, building up to 220 mg three times a day. At this dosage he was able, for the first time in 20 years, to dispense with his harness, and has continued to do so since.

Comment

This case shows that levodopa can suppress a tremor similar to that of Parkinson's disease but without basal ganglia lesions, and that its suppressive effect is greater than is usual in Parkinson's disease. This

Continuous two-hour accelerometric recording in case of tremor suppressed with levodopa. Time scale is not linear, being compressed and expanded to show important events indicated.

implies that the sites of action of levodopa are more widespread than is thought. In neurological practice similar tremors are most commonly seen in multiple sclerosis with brain stem plaques and in brain stem vascular disease. Unfortunately, when there are multiple lesions or widespread damage from a single lesion our experience is that treatment with levodopa is neither as successful nor predictable.

- ¹ Holmes G. On certain tremors in organic cerebral lesions. *Brain* 1904;27:360-75.
- ² Struppler A, Velho-Groneberg P, Claussen M. Clinic and pathophysiology of tremor. In: Birkmayer W, Hornykiewicz O, eds. *Advances in parkinsonism*. Philadelphia: W B Saunders, 1974:287-302.
- ³ Markham CM, Treciokas LJ, Diamond SG. Parkinson's disease and levodopa. A five year follow-up and review (medical progress). *West J Med* 1974;121:188-206.
- ⁴ Evarts EV. Neurophysiological mechanisms in Parkinson's disease. In: Birkmayer W, Hornykiewicz O, eds. *Advances in parkinsonism*. Philadelphia: W B Saunders, 1974:37-54.
- ⁵ Goldberger ME, Growden JH. Tremor at rest following cerebellar lesions in monkeys: effect of L-dopa administration. *Brain Res* 1971;27:183-7.

(Accepted 14 August 1980)

National Hospital, Queen Square, London WC1N 3BG, and MRC Hearing and Balance Unit, Institute of Neurology, National Hospital, London WC1N 3BG

L J FINDLEY, MB, MRCP, senior registrar

M A GRETTY, BA, PHD, senior scientist, MRC department of hearing and balance

Adverse reaction to bupivacaine: complication of intravenous regional analgesia

Bupivacaine has been suggested to be the agent of choice for intravenous regional analgesia because of its effectiveness and freedom from adverse reactions.^{1,2} I report a case of unexpected neurotoxicity after intravenous regional analgesia with bupivacaine.

Case report

A healthy 15-year-old West Indian boy weighing 63 kg presented with a displaced epiphyseal fracture of the distal end of radius. He was taking no medication, had no known allergies, and was sickle-cell negative. No pre-medicant drugs were given. A tourniquet cuff was applied to the upper part of the arm. A 23 G indwelling needle was placed in a vein on the dorsum of the right hand. The arm was exsanguinated by raising it, the cuff was inflated to a pressure of 200 mm Hg, and 1.5 mg/kg 0.25% bupivacaine was injected through the indwelling needle (total dose 95 mg). Complete analgesia resulted and the fracture was reduced and immobilised without any discomfort to the patient.

Forty minutes after the injection of anaesthetic the cuff was released without reinflation. Within 45 seconds of releasing the cuff the patient began to talk excitably with a continuous dialogue of seemingly unrelated personal events. He was completely unresponsive to commands and apparently unaware of his surroundings. His speech was rapid, without slurring, and was concerned with events and grievances at his place of work, his sporting skills, and other personal problems. At the same time he developed irregular twitching of both arms and legs and, to a lesser degree, of the trunk. This hyperexcitable state was considered to be preictal, and after three minutes diazepam 10 mg was given intravenously to reduce the likelihood of a major convulsion. The symptoms persisted. After 12 minutes another 10 mg diazepam was given. The twitching diminished but the confused speech continued. Forty-five minutes after deflation of the cuff the patient was restless and talking irrationally and excitedly. Twitching was now very infrequent. He was sedated with 100 mg chlorpromazine given intravenously in 25-mg increments. He slept soundly until the next morning and had no further twitching. His heart rate, blood pressure, and respiratory rate and pattern remained stable throughout. He was discharged the next day.

Comment

Presumably bupivacaine was released into the circulation after the cuff was deflated, since the symptoms that followed immediately were similar to the neurotoxic effects of other intravenous local anaesthetics.³ Tremor and convulsions have been reported after epidural block with

bupivacaine, and neurotoxic reactions after the use of lignocaine for intravenous regional analgesia. Symptoms have ranged from headache and dizziness to loss of consciousness and convulsions.²⁻⁴ Reports of adverse reactions after intravenous regional analgesia with bupivacaine are few and the symptoms minimal.¹ Ware reported mild transient drowsiness after release of the cuff in only one patient out of a total of 2500 using 1.5 mg/kg of 0.2% bupivacaine for intravenous regional analgesia.²

The low incidence of adverse effects is thought to be due to the high protein-binding property of bupivacaine. Normally over 90% is bound to plasma proteins and consequently very little "free" drug is available for systemic action. Measurements of peak plasma concentrations after intravenous regional analgesia with bupivacaine also confirm a wide safety margin. Peak concentrations occur at about three minutes after deflation of the cuff (840 ng/ml). That is about half the accepted minimum toxic concentration for this drug (1600 ng/ml).¹⁻⁵

¹ Ware RJ, Caldwell J. Clinical and pharmacological studies of intravenous regional analgesia using bupivacaine. *Br J Anaesth* 1976;**48**:1124-5.

² Ware RJ. Intravenous regional analgesia using bupivacaine. A double blind comparison with lignocaine. *Anaesthesia* 1979;**34**:231-5.

³ Foldes FF, Molloy R, McNall PG, Koukal LR. Comparison of toxicity of intravenously given local anaesthetic agents in man. *JAMA* 1960;**172**:1493-8.

⁴ Bell HM, Slater EM, Harris WH. Regional anaesthesia with intravenous lidocaine. *JAMA* 1963;**186**:544-9.

⁵ Reynolds F. A comparison of the potential toxicity of bupivacaine, lignocaine and mepivacaine during epidural blockade for surgery. *Br J Anaesth* 1971;**43**:567-71.

(Accepted 1 September 1980)

Whittington Hospital, London N19 5NF

A M HENDERSON, BSC, MB, senior house officer (present appointment: registrar in anaesthesia, University College Hospital, London WC1 6AU)

Long-term dietary treatment of hyperlipidaemia in patients treated with chronic haemodialysis

Hyperlipidaemia is common among patients undergoing haemodialysis for chronic renal failure.¹ We have reported a successful reduction of plasma lipid concentrations in such patients by dietary measures over a one-month period,^{1,2} but we were uncertain about the likelihood of compliance over a longer time. Three years ago we recommended a lipid-lowering diet to all patients on our dialysis programme. We report here the compliance with, and effects of, this diet in 39 patients reviewed 32 months after receiving this advice.

Patients, methods, and results

Dietary advice was originally given by a dietitian to 77 men and 54 women on maintenance haemodialysis. The recommended diet aimed to reduce the proportion of total energy taken as fat, to change the ratio of saturated to polyunsaturated fat from 3:1 to 1:1, and to reduce daily cholesterol intake to less than 300 mg. The experimental diet was made isocaloric

with the previous diet by increasing carbohydrate to compensate for reduced fat intake. Forty-seven of the original group received successful transplants and 23 died (10 of cardiovascular disease). From the remaining 61 patients, 39 were available for study after a mean interval of 32 months (22 men, 17 women; mean age ($\pm$ 1 SD) 43 $\pm$ 10 years). Blood was taken at a routine visit to the dialysis clinic for measuring total cholesterol, cholesterol in the lipoprotein fractions, and triglycerides using methods previously described.³ Dietary compliance was assessed by measuring the percentage of linoleic acid in the fasting triglyceride fatty acids.⁴ It was also assessed qualitatively in 38 patients by the dietitian, who divided them into four groups (group 1, good compliance; group 2, fair compliance; group 3, poor compliance; group 4, no compliance). The dietitian did not know the biochemical results when she saw the patients. Statistical analysis was by Student's *t* test.

Eleven patients were in group 1, 20 in group 2, seven in group 3, and none in group 4. Linoleic acid, expressed as percentage of total triglyceride fatty acids, was 25.6 $\pm$ 7.4%, 21.3 $\pm$ 8.2%, and 14.7 $\pm$ 6.6% for groups 1, 2, and 3 respectively, agreeing with the dietitian's grading. Total cholesterol in all 39 patients fell from 6.2 $\pm$ 1.5 mmol/l (242 $\pm$ 59 mg/100 ml) before to 5.1 $\pm$ 1.3 mmol/l (199 $\pm$ 51 mg/100 ml) at the end of the dietary period (p < 0.0002). Mean values of total cholesterol and triglycerides before and after diet and of cholesterol fractions after diet are shown in the table. Overall triglyceride concentrations were identical before and after the diet (2.5 $\pm$ 1.0 mmol/l, 213 $\pm$ 85 mg/100 ml) but concentrations were significantly lower after diet in group 1 than in group 3 (see table). Mean body weights (measured after dialysis) were identical before and after the dietary period (59 kg). There were no significant changes in body weight in any of the dietary groups.

Comment

The diet was acceptable to most patients; those who complied best showed a reduction in total cholesterol and a more "favourable" ratio of high density lipoprotein cholesterol to low density lipoprotein cholesterol. Although there was no overall reduction in triglycerides, concentrations were lowest in those with the best dietary compliance and vice versa. Diet is an effective and acceptable treatment for dialysis hyperlipidaemia, but any long-term clinical benefit of lowering lipid concentrations in these patients remains unproved.

We thank Robin Carter and Richard Jelfs, who performed the laboratory assays; Joan Osmond for administrative help; and Alan Cahill for taking the blood samples.

¹ Gokal R, Mann JI, Oliver DO, Ledingham JGG. Dietary treatment of hyperlipidaemia in chronic haemodialysis patients. *Am J Clin Nutr* 1978;**31**:1915-8.

² Gokal R, Mann JI, Oliver DO, Ledingham JGG, Carter RD. Treatment of hyperlipidaemia in patients on chronic haemodialysis. *Br Med J* 1978;**ii**:82-3.

³ Gokal R, Mann JI, Moore RA, Morris PJ. Hyperlipidaemia following renal transplantation. *Quart J Med* 1979;**48**:507-12.

⁴ Moore RA, Oppert S, Eaton P, Mann JI. Triglyceride fatty acids confirm a change in dietary fat. *Clin Endocrinol* 1977;**7**:143-9.

(Accepted 18 August 1980)

Nuffield Department of Medicine, Radcliffe Infirmary, and Renal Unit, Churchill Hospital, Headington, Oxford

T L DORNAN, MRCP, research fellow

R GOKAL, MD, research fellow (now lecturer in medicine, Royal Victoria Infirmary, Newcastle upon Tyne)

J S PEARCE, BSC, dietitian

D O OLIVER, FRCP, consultant physician

J G G LEDINGHAM, FRCP, consultant physician

J I MANN, DM, university lecturer in social and community medicine

Total cholesterol, HDL cholesterol, and triglyceride concentrations and ratios of HDL cholesterol to LDL cholesterol for 38 patients subdivided according to the dietitian's assessment of dietary compliance

Dietary compliance	Total cholesterol (mmol/l)				HDL cholesterol (mmol/l) (after diet)	HDL:LDL ratio (after diet)	Triglycerides (mmol/l)		
	Before diet	After diet	Change	p			Before diet	After diet	Change
Good (n = 11)	6.4 $\pm$ 1.2 6.0	5.0 $\pm$ 1.0 4.7	-1.4	<0.002	1.5 $\pm$ 0.5 1.3	0.54	2.4 $\pm$ 0.7 2.5	2.1 $\pm$ 0.8*	-0.3
Fair (n = 20)	6.0 $\pm$ 1.9 6.2	5.0 $\pm$ 1.1 6.2	-1.3	<0.0004	1.3 $\pm$ 0.3 1.3	0.51	2.3 $\pm$ 1.1 2.9	2.3 $\pm$ 0.6 3.5	-0.2
Poor (n = 7)	6.2 $\pm$ 1.1	6.2 $\pm$ 1.7	0	NS	1.3 $\pm$ 0.4	0.33	3.5 $\pm$ 1.4	3.5 $\pm$ 1.5	0.6

HDL = High density lipoprotein. LDL = Low density lipoprotein.

* p < 0.02 compared with triglyceride concentrations after diet in "poor compliance" group.

Conversion: SI to traditional units—Cholesterol: 1 mmol/l $\approx$ 38.6 mg/100 ml. Triglycerides: 1 mmol/l $\approx$ 88.5 mg/100 ml.